OOIR: Observatory of International Research

Papers

(The TQCC of Trends in Pharmacological Sciences is 18. The table below lists those papers that are above that threshold based on CrossRef citation counts [max. 250 papers]. The publications cover those that have been published in the past four years, i.e., from 2022-06-01 to 2026-06-01.)

Article	Citations
Subscription and Copyright Information	670
Shearing of surface mucin saps tumor cell strength	571
Subscription and Copyright Information	279
Advisory Board and Contents	245
Subscription and Copyright Information	245
Subscription and Copyright Information	219
Subscription and Copyright Information	206
DOT1L: orchestrating methylation-dependent radiotheRAPy responses via BRCA1	200
Structural asymmetry in FGF23 signaling	188
Muscarinic receptors: from clinic to bench to clinic	183
Cancer pathogenesis and phase targeting through condensate fragility	166
Monitoring neurodegeneration through brain-derived extracellular vesicles in biofluids	151
Swinging the SWI/SNF complexes for cancer therapy	147
Ensifentrine (Ohtuvayre™) for chronic obstructive pulmonary disease	140
Advancing chemical carcinogenicity prediction modeling: opportunities and challenges	139
Compstatins: the dawn of clinical C3-targeted complement inhibition	131
Targeting complement in neurodegeneration: challenges, risks, and strategies	125
Therapeutic inhibition of ferroptosis in neurodegenerative disease	114
Structural pharmacology and mechanisms of GLP-1R signaling	110
Advisory Board and Contents	106
Direct in vivo CAR T cell engineering	106
Engineering ACE2 decoy receptors to combat viral escapability	105
Leveraging human microbiomes for disease prediction and treatment	105
The B7-H3 (CD276) pathway: emerging biology and clinical therapeutics	104
Advisory Board and Contents	103

HSV-1 as a gene delivery platform for cancer gene therapy	101
Mechanistic considerations for adenosine-lidocaine-magnesium (ALM) in controlling coagulopathy	99
A smart hospital-driven approach to precision pharmacovigilance	95
Advisory Board and Contents	95
Programmable CAR immunotherapies for neurodegenerative proteinopathies	94
Chemically modified neoantigen-based immunotherapy for targeting KRASG12C-driven tumors	89
A deep dive into degrader-induced protein-protein interfaces	87
Phenotypic approaches for CNS drugs	87
A perspective on psychedelic teratogenicity: the utility of zebrafish models	85
Nemolizumab (Nemluvio®) for prurigo nodularis	84
Ribosome-directed cancer therapies: the tip of the iceberg?	76
Genetically engineered loaded extracellular vesicles for drug delivery	73
Optogenetic engineering for precision cancer immunotherapy	72
Subscription and Copyright Information	69
Thriving as members of under-represented groups in pharmacology-related careers	67
Emerging approaches to induce immune tolerance to therapeutic proteins	66
Mentoring future science leaders to thrive	66
Subscription and Copyright Information	66
Now you serine, now you don't	66
Subscription and Copyright Information	64
Alzheimer’s therapeutic development: shifting neurodegeneration to neuroregeneration	58
Deubiquitinating enzymes as therapeutic targets in diabetic nephropathy	58
The structure, function, and pharmacology of MRGPRs	58
GPR35, ally of the anti-ischemic ATPIF1-ATP synthase interaction	58
Advancing non-destructive analysis of 3D printed medicines	56
Bimetallic nanoadjuvants for cancer vaccines	56
Targeting AMPK as a potential treatment for hepatic fibrosis in MASLD	55
Piezo1: structural pharmacology and mechanotransduction mechanisms	55
Suzetrigine for moderate to severe acute pain	53
Mechanistic insights into nitazenes at the μ-opioid receptor	52
Could dexmedetomidine be repurposed as a glymphatic enhancer?	50
Autologous, allogeneic, in vivo CAR for autoimmune diseases	49
Molecular glues evolve from serendipity to rational design	47
Targeting metabolic vulnerabilities with advanced delivery systems	43
The road less traveled: activating an oncogenic kinase	43
Advisory Board and Contents	43
Salt-inducible kinases: new players in pulmonary arterial hypertension?	42
Hepatic mitochondrial reductive stress in the pathogenesis and treatment of steatotic liver disease	42
The promise of targeted protein degradation approaches	42
Targeting LKB1/STK11-mutant cancer: distinct metabolism, microenvironment, and therapeutic resistance	41
Inhalable neutralizing antibodies – promising approach to combating respiratory viral infections	40
Promising neuroimmune targets and drugs for CNS diseases	40
Advisory Board and Contents	40
Treg-directed cancer immunotherapy beyond immune checkpoints: progress and opportunities	40
Mavacamten improves symptoms in obstructive hypertrophic cardiomyopathy patients	40
Subscription and Copyright Information	39
Monkeypox: potential vaccine development strategies	38
PDE4 modulates muscle signaling in cancer cachexia	38
Advisory Board and Contents	38
A novel function of the M2 muscarinic receptor	37

Validation of agent-based models of surface receptor oligomerisation	37
Targeting the assembly of biomolecules: condensate-based drug discovery	36
Beyond G protein and arrestin: GRK2-biased β₂AR signaling	36
The end of the beginning in understanding SLC22 polyspecificity	36
Protein acylations in cancer immunity: effects and therapeutic opportunities	36
Decoding pseudouridine: an emerging target for therapeutic development	35
BTK inhibitors: past, present, and future	33
Artificial intelligence in rare diseases: toward clinical impact	33
Frizzleds act as dynamic pharmacological entities	33
Tackling microbial iron homeostasis: novel antimicrobial strategies	33
Advisory Board and Contents	32
SEAKER cells coordinate cellular immunotherapy with localized chemotherapy	31
Advisory Board and Contents	30
Subscription and Copyright Information	30
Demographic diversity in platelet function and response to antiplatelet therapy	29
Metabolic regulation in normal and leukemic stem cells	29
Neurofilament light chain as a biomarker of chemotherapy-induced peripheral neuropathy	29
GPR35: from enigma to therapeutic target	29
Histone lysine acetyltransferase inhibitors: an emerging class of drugs for cancer therapy	29
Topical difamilast for the treatment of mild-to-moderate atopic dermatitis	29
Voltage-gated ion channels in epilepsies: circuit dysfunctions and treatments	28
Development of PROTACs using computational approaches	28
Recent advances in generative biology for biotherapeutic discovery	28
Eflornithine for treatment of high-risk neuroblastoma	28
Subscription and Copyright Information	27
Subscription and Copyright Information	27
Tackling chronic kidney disease in diabetic patients with finerenone	27
Biologics and cardiac disease: challenges and opportunities	26
Visceral obesity and HFpEF: targets and therapeutic opportunities	26
Subscription and Copyright Information	26
Modulation of Wnt–β-catenin signaling with antibodies: therapeutic opportunities and challenges	26
Targeting plasma membrane cholesterol as a novel anticancer therapy	26
A novel anticancer pharmacological agent targeting mitochondrial complex I	26
Magnesium for disease treatment and prevention: emerging mechanisms and opportunities	25
Neutrophil extracellular traps in wound healing	24
Harnessing associative learning paradigms to optimize drug treatment	24
Subscription and Copyright Information	24
The structure, function, and pharmacology of SK channel family	24
Targeting sensory neuron GPCRs for peripheral neuropathic pain	24
Recent advancements in vaccine research and development	24
Oteseconazole (VIVOJA) for prevention of recurrent vulvovaginal candidiasis	24
Boosting CAR-T cell therapy through vaccine synergy	24
Circadian biology to advance therapeutics for mood disorders	23
Taming PRMT5–adaptor protein interactions	23
Multitargeting neuroimmune pathways: novel candidates for chronic pain relief	23
Challenges and opportunities associated with rare-variant pharmacogenomics	22
Crosstalk between androgen receptor and protein kinase G signaling in bone: implications for osteoporosis therapy	22
Therapeutic antibodies targeting G protein-coupled receptors	22
Emerging strategies for engineering Escherichia coli Nissle 1917-based therapeutics	22
NLRP3 and pyroptosis blockers for treating inflammatory diseases	21
GABAA receptors as targets for treating affective and cognitive symptoms of depression	21
WEE-family kinases in cancer: synthetic lethal interactions and drug discovery	21
The ABCs of psychedelics: a preclinical roadmap for drug discovery	20
Targeted protein degrader development for cancer: advances, challenges, and opportunities	20
Targeting competitive Fe–S regulation to treat Friedreich’s ataxia	20
Harnessing UBR5 for targeted protein degradation of key transcriptional regulators	20
Subscription and Copyright Information	20
Advisory Board and Contents	20
The structure and function of YTHDF epitranscriptomic m6A readers	19
Potential for targeting small heat shock protein modifications	19
Odorant receptors as potential drug targets	19
β-Arrestins and disease-linked variants: opportunities for targeted modulation	18
Targeting peptide–HLA complexes for precision immunotherapy	18
Advisory Board and Contents	18
Subscription and Copyright Information	18
Glymphatic-stagnated edema induced by traumatic brain injury	18
Advisory Board and Contents	18
Drugging cold-response networks for neuroprotection	18
Induced proximity for dephosphorylation	18
GPCR-dependent and -independent arrestin signaling	18
Malolactone strikes: K-Ras-G12D's Achilles' heel	18
KRASG12C/mTORC1 inhibition: a powerful duo in NSCLC therapeutics	18